Organization | Cinnagen

Cinnagen Report issue

For profit Phase 1 Phase 3

Founded: Tehran Iran (Islamic Republic of) (1994)

Status: No NME R&D (1994)

Organization Overview

First Clinical Trial

2015

NCT03172325

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Cinnagen

Active Ingredients

Drugs in Phase 3 Trials (22)

adalimumab (humira) (2 trials)

advax (2 trials)

b complex vitamin (1 trial)

carboplatin (paraplatin) (1 trial)

cetuximab (erbitux) (1 trial)

cobalamin (1 trial)

covid19 recombinant spike protein (2 trials)

docetaxel (taxotere) (1 trial)

epoetin (Epogen) (1 trial)

fluorouracil (efudex) (1 trial)

folic acid (1 trial)

irinotecan (Camptosar) (1 trial)

leucovorin (1 trial)

liraglutide (victoza) (1 trial)

metformin (glucophage) (1 trial)

methotrexate (1 trial)

mrna-1273 (1 trial)

ocrelizumab (ocrevus) (1 trial)

pertuzumab (perjeta) (1 trial)

prednisone (meticorten) (1 trial)

somatropin (protropin) (1 trial)

trastuzumab (herceptin) (1 trial)

Drugs in Phase 1 Trials (1)

peginterferon beta-1a (Plegridy) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Anemia (Phase 3)

Arthritis (Phase 3)

Arthritis, Rheumatoid (Phase 3)

Colorectal Neoplasms (Phase 3)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Dwarfism, Pituitary (Phase 3)

Endocrine System Diseases (Phase 3)

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 12
# of Trial APIs: 23